Article

In Young People, Sudden Cardiac Death can be Caused by Gene Defects

Author(s):

Researchers have discovered that ion channel disorders may account for one-third of unexplainable sudden cardiac death in young people.

Researchers from Germany’s Institute for Forensic Medicine have discovered that ion channel disorders like long QT syndromes, catecholaminergic polymorphic ventricular tachycardia, and the Brugada syndrome may account for one-third of unexplainable sudden cardiac death (SCD) in young people.

The researchers subcategorized cardiac gene defects into two groups: disorders that are accompanied by structural cardiovascular abnormalities, such as arrhythmogenic right ventricular dysplasia and hypertrophic cardiomyopathy; and disorders that do not have cardiac changes detectable at the time of death with a cause that is mostly arrhythmogenic, like the ion channels responsible for one-third of the SCD cases in young people.

The team of researchers found that post-mortem genetic screening for the presence of sequence variations in cardiac ion channel genes was helpful in ascertaining the cause of SCD in otherwise unclear cases.

SCD is listed as one of the most common causes of death in Europe, and although it usually happens among older people, 5-10% of cases there occur in young and apparently healthy people. The study adds that as many as 7,000 asymptomatic children in the US die from SCD each year, almost half of whom never show earlier symptoms.

In their findings, the researchers discussed that the majority of the ion-channel diseases are hereditary with an autosomal-dominant transmission, meaning that half of the children of individuals affected by SCD will be impacted as well.

In the event that sequence variations are identified, family members of the deceased should then undergo further medical tests. The researchers hope that these new findings will allow for individual risk analysis among impacted family members, who can then be provided with prophylactic treatment, such as an implantable cardioverter defibrillator.

For more information, click here.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.